Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma

Hirohito Yano,1 Jun Shinoda,2 and Toru Iwama1

1Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan;
2Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Department of Neurosurgery, Kizawa Memorial Hospital, Minokamo, Gifu, Japan

Abstract
Positron emission tomography (PET) is being increasingly utilized for the management of brain tumors. Herein, we primarily review our previous studies on the use of PET in glioma that utilize three types of tracers: 11C-methionine (MET), 11C-choline, and 18F-fluorodeoxyglucose. These studies included aspects such as tumor behavior, diagnosis, grade of malignancy, spread and invasion, viability, and genetic deletions; moreover, they also evaluated PET as a tool for planning radiation therapy (RT) and determining its outcome. MET-PET in particular is considered to be the most informative for diagnosis and therapeutic decision-making for glioma patients; it is therefore considered crucial for brain tumor therapy. MET-PET is expected to be widely used for brain tumor patients going forward.

Key words: positron emission tomography, methionine, fluorodeoxyglucose, choline, glioma

Introduction
There are several modalities used to diagnose brain tumors, among which positron emission tomography (PET) is one of the most reliable and useful for providing clinically important information. The role of PET-based examination in clinical neuro-oncology is growing in importance for tumor diagnosis as well as for the evaluation of tumor malignancy, invasion, and metabolism. This information is valuable not only to plan therapeutic interventions, but also to evaluate treatment success and predict prognosis. PET is particularly useful for the diagnosis of glioma; it was previously reported that PET delineates gliomas more accurately than magnetic resonance imaging (MRI). In this review, we summarize our previous findings regarding the use of PET in gliomas, where we used three types of radiolabeled tracers: 11C-methionine (MET), 11C-choline (CHO), and 18F-fluorodeoxyglucose (FDG). These tracers are retained in tumor cells via mechanisms that are distinct from normal cells. Moreover, using these three types of tracers in combination can potentially provide more information about a tumor's nature and behavior than MRI is likely to offer.

MET-PET
MET-PET is critical for evaluating the tumor grade and proliferative activity, as well as to image the size and spread of the glioma. It has advantages in terms of selective labeling of the tumor as distinguished from normal brain tissue, even in cases of no contrast enhancement on MRI. There are three proposed explanations for the mechanism of MET uptake in tissues: active transport, passive diffusion, and stagnation. First, MET is taken up by tumor cells through an energy-independent L-type amino acid transporter system as well as the sodium-dependent transporter system (A and B0). This active transport is dependent on cell proliferation and tumor malignancy. Second, passive diffusion of MET is attributed to the disruption of the blood-brain-barrier (BBB) in the lesions. Third, MET stagnation in regional vascular beds depends on the blood volume. These three mechanisms combined lead to the accumulation of MET in tumor cells.

CHO-PET
Choline is an important component of phospholipids in the cell membrane; accordingly, increased levels of this component are required in highly proliferating brain tumor cells. The mechanism of CHO uptake in gliomas is thought to be caused BBB
Clinical Utility of PET in Glioma Management

FDG-PET

18F-FDG-PET is generally used to detect systemic cancer. The mechanism of FDG uptake into cells is dependent on the activity of glucose transporters, hexokinases (HKs), and phosphatases. FDG enters cells via glucose transporters and is then phosphorylated by HK to FDG-6-phosphate, which cannot be metabolized further in the glycolytic pathway and remains in the cytoplasm. Accordingly, enhanced uptake of FDG in highly malignant tumors contrasts clearly with normal tissues on 18F-FDG-PET imaging. However, because normal brain tissues also actively absorb glucose, contrast expression of malignant glioma with FDG-PET is less than that with MET-PET.

Tumor detection

MET-PET has an advantage over FDG-PET and CHO-PET because lesions that uptake MET are relatively easy to detect in gliomas of all grades owing to their contrast differences relative to the surrounding normal brain. On the other hand, since FDG is diffusely accumulated in the normal brain and the dynamic state of CHO resembles the gadolinium (Gd)-based contrast medium, both tracers are less effective at identifying low-grade gliomas.

For evaluating lesion viability, the standardized uptake value (SUV) of the tracer in the region of interest (ROI) is analyzed. The SUV is the concentration of the tracer in the ROI at a fixed time point divided by the injected dose, normalized to the patient’s measured weight. The tumor-to-normal (T/N) ratios of the MET, CHO, and FDG SUVs are calculated by dividing the maximum SUV of the tumor by the mean SUV of the contralateral normal frontal cortex. The maximum SUVs of the tumors are selected as indicators of the highest tracer accumulation, and are used instead of the mean SUVs to minimize the influence of tumor heterogeneity. In one study, the T/N ratio was used instead of the absolute SUV because of high, unexplained inter-subject SUV variability. Another study investigated the optimal threshold for the mean MET uptake ratio relative to the corresponding contralateral normal brain to discriminate the tumor from the normal brain, and found that using a T/N ratio threshold of 1.3 as an indicator for performing stereotactic biopsy demonstrated a sensitivity and specificity of 87% and 89% for the detection of astrocytic tumors, respectively.

Tumor grading

Our previous study showed that FDG-PET was useful for differentiating glioblastoma multiforme (GBM) from a diffuse astrocytoma (DA) and anaplastic astrocytoma (AA). The FDG T/N ratios in DA, AA, and GBM were 0.79 ± 0.08, 1.27 ± 0.46, and 1.88 ± 0.78, respectively. Significant differences were observed between DA and GBM (P = 0.001), and between AA and GBM (P = 0.05). However, FDG-PET could not distinguish between oligodendrogial tumors (oligodendroglioma [OD]: 1.03 ± 0.40 vs. anaplastic OD [AOD]: 1.71 ± 1.09) or between oligoastrocytic tumors (oligoastrocytoma [OA]: 1.00 ± 0.45 vs. anaplastic OA [AOA]: 0.85 ± 0.15). In a previous study, Kim et al. reported that significant differences in glioma grades could not be detected with FDG-PET; conversely, other reports have shown significant correlations between the glioma grade and FDG uptake.

Similarly, it was reported that MET-PET could differentiate GBM from DA and AA. MET T/N ratios in DA, AA, and GBM were 2.24 ± 0.90, 3.03 ± 1.02, and 5.03 ± 1.65, respectively. Significant differences were observed between DA and GBM (P < 0.001) and between AA and GBM (P < 0.001). Significant differences were not observed between oligodendrogial tumors (OD: 3.95 ± 1.60; AOD: 4.46 ± 1.55) or between oligoastrocytic tumors (OA: 2.60 ± 0.91; AOA: 2.83 ± 0.99). However, significant differences were observed between grade II tumors (DA vs. OD, P < 0.05) as well as between grade III tumors (AA vs. AOD, P < 0.05) on MET-PET. Based on these results, MET has the potential to evaluate both the grades and types of astrocytic tumors.

Tumor growth potential

Tumor proliferation is generally evaluated by using the MIB-1 labeling index (LI) via immunohistochemistry. We previously examined the relationship between PET T/N ratio and MIB-1 LI, and found a significant correlation only in astrocytic tumors that included 13 cases of DAs, 14 of AAs, and 7 of GBMs; no correlation was found in oligodendrogial tumors. Correlation coefficients in astrocytic tumors between MIB-1 LI and T/N ratios using MET, FDG, and CHO were 0.64 (P < 0.001), 0.71 (P < 0.001), and 0.64 (P < 0.001), respectively. Furthermore, the same relationship was examined in a limited series of grade II gliomas including 21 cases of DAs, 12 of ODs, and 16 of OAs. No significant correlation was found between the MET T/N ratio and MIB-1 LI.
There were significant differences between grades II and III (P < 0.01) and between grades II and IV (P < 0.01); however, there was no significant difference between grades III and IV. In grade II tumors, lower cell density and lower proliferation resulted in a smaller hot MET area on MET-PET. In contrast, it is extremely likely that the areas of the hot MET lesions that do not exhibit Gd enhancement in high-grade tumors are associated with the extent of tumor cell invasion, and are reflective of substantial cell density (rather than high proliferative activity) that is not necessarily correlated with a higher MET SUV given the nature of MET uptake mechanisms. Since the value of MET-AR was larger than that of CHO-AR in each tumor grade, MET-PET appears to be superior to CHO-PET in terms of evaluating the spread of astrocytic tumors.

With respect to evaluating the tumor spread in GBM cases, we compared the MET uptake area to the Gd enhancement area and to the high-intensity area on T2-weighted PET-MRI fusion images; the MET uptake area completely enveloped the Gd-enhanced area. In nine GBM cases out of 10, the MET uptake area enfolded the outer side of the Gd-enhanced area and expanded it by an additional 30 mm. In contrast, the Gd-enhanced area coincided with only 58.6% of MET uptake areas on average. Based on these results, we identified three cases of possible GBM recurrences after complete resection; they presented as new Gd-enhanced lesions in the MET uptake area at the edge of the surgical removal cavity. Hence, MET-PET was apparently able to detect the metabolic abnormalities in residual tumor cells before local tumor recurrence was discernible on MRI.

In only one GBM case out of 10, the MET uptake area was completely within the T2-high area; in the remaining nine cases, the MET uptake area did not coincide with the T2-high areas. We posited that the T2-high region beyond the MET uptake area was mainly peritumoral edema. However, the MET uptake area observed beyond the T2-high area likely reflected invasive tumor cells. Accordingly, MET-PET appears to outline...
the true extent of the viable tumor tissue more precisely than MRI.\(^{23}\)

With respect to planning glioma surgery using PET data, Pirotte et al.\(^{25}\) performed high-grade glioma (HGG) resections under the guidance of PET (MET or FDG) combined with MRI scans in 66 consecutive patients. MET and FDG were used in 43 and 23 cases, respectively; these markers contributed to defining the target lesion in 79% and 74% of these surgeries, respectively. Furthermore, patients who underwent total PET resection exhibited a significantly longer survival than those who underwent a subtotal/partial PET resection (median survival: 32.5 vs. 17.6 months, respectively; \(P = 0.0001\)). In contrast, no significant difference in survival was observed between patients with or without residual postoperative MRI contrast enhancement (median survival: 26.4 vs. 32.8 months, respectively; \(P = 0.1105\)). The authors concluded that complete resection of the PET tracer uptake area in HGGs may contribute to longer survival, and that PET delineates HGGs more reliably than an MRI contrast enhancement.

**MET-PET in oligodendroglial tumors**

MET-PET shows no significant differences between grades and proliferative activities of oligodendrogial tumors; however, MET T/N ratios in ODs/AODs have

\[\text{Fig. 1} \quad \text{Positron emission tomography and magnetic resonance imaging fusion images with gadolinium enhancement of astrocytoma (grade II according to the World Health Organization [WHO] criteria) (A and B), anaplastic astrocytoma (WHO grade III) (C and D), and glioblastoma multiforme (WHO grade IV) (E and F). The upper panels illustrate the use of } ^{11}\text{C-choline-PET (A, C, and E) while the lower panels demonstrate } ^{11}\text{C-methionine-PET (B, D, and F). The white lines in C and D were manually drawn using the Image J software to measure each hot lesion and the whole brain on the same slice. The numbers in the lower-right of each panel represent the percentages of the detected lesion areas relative to the whole brain areas (previously unpublished data from our group).}\]
been reported to be significantly higher than those in DAs/AAs within each World Health Organization (WHO) grade.\textsuperscript{26} In terms of the differences in MET T/N ratios, vascular proliferation and tumor angiogenesis should be taken into consideration.\textsuperscript{2}\textsuperscript{26} Immunohistochemical studies of factor VIII revealed higher microvessel counts in ODs than in astrocytic tumors.\textsuperscript{26} Furthermore, a perfusion study showed that the tumor blood volumes in ODs were significantly higher than those in DAs.\textsuperscript{27} It was suggested that the high blood volume in ODs caused by numerous large intratumoral blood vessels was associated not only with high MET uptake but also with rapid wash-out compared to DA.\textsuperscript{28} Therefore, we routinely performed dynamic MET-PET scanning, where image acquisition was performed in three consecutive phases (5–15, 15–25, and 25–35 min after intravenous injection of MET). Consequently, a significant dynamic decrease of MET T/N ratios was found in oligodendrocytic tumors (Fig. 3). This finding was also observed in meningiomas, although these are easier to identify clinically. A significant dynamic increase of MET T/N ratios was also observed in GBM and central nervous system lymphoma,\textsuperscript{29} which are often indistinguishable on MRI to the extent that additional clinical data and other diagnostic modalities are required. Next, we performed dynamic MET-PET studies on GBM patients with oligodendrogial components (GBMO),\textsuperscript{30} whose prognoses remain controversial to date. This GBMO study showed that the dynamic MET signal tended to decrease over time; these changes resembled those in the above-mentioned oligodendrogial tumors. Accordingly, GBMO may be a possible differential diagnosis when dynamic MET-PET shows a decreasing pattern.\textsuperscript{30}

1p/19q loss of heterozygosity (LOH)

The 2016 World Health Organization Classification of Tumors of the Central Nervous System identified the 1p/19q co-deletion as one of the essential molecular diagnostic markers of OD and AOD.\textsuperscript{31} Because analysis of the surgical specimens can validate the presence or absence of LOH, preoperative prediction of 1p/19q LOH by using a noninvasive imaging technique is of profound importance for improving the clinical management of ODs.\textsuperscript{32} Saito et al.\textsuperscript{33} reported that MET uptake correlated with 1p/19q LOH in ODs; the mean T/N ratios of tumors with and without 1p/19q LOH were 3.100 ± 1.163 and 2.473 ± 1.193, respectively. The former was greater than the latter in all tumors including grades II and III;\textsuperscript{28} however, statistical significance was only observed in grade II tumors. Multivariate analyses revealed that only the threshold T/N ratio value used in the study (2.46) was an independent predictive factor with respect to the presence of 1p/19q LOH in all tumors and also within grade II tumors.\textsuperscript{33} These findings may reflect not only a greater tumor blood volume but an increased

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.jpg}
\caption{Graphs showing the $^{11}$C-choline (CHO)-area ratio (A) and $^{11}$C-methionine (MET)-area ratio (B) for each tumor grade. (a: $P < 0.0001$, b: $P < 0.02$, and c: $P < 0.01$).}
\end{figure}
rate of MET transport from the tumor endothelial cells, suggesting a higher metabolic demand. The T/N ratio of grade III ODs was influenced not only by 1p/19q LOH but also by further angiogenesis, increased tumor blood, and increased transport of MET from the tumor endothelial cells, which are associated with increased malignancy. On the other hand, a previous study showed that the high glucose uptake demonstrated by FDG-PET is closely associated with 1p/19q LOH in WHO Grade II gliomas. High FDG uptake was observed in six of eight WHO grade II gliomas with 1p/19q LOH but in none of the eight WHO grade II gliomas without 1p/19q LOH; using FDG update as a prediction method showed a sensitivity of 75% and a specificity of 100%. Hence, MET-PET and FDG-PET are considered non-invasive imaging modalities available before surgery to serve as prognostic and predictive tools.

**Radiation therapy (RT) planning**

MET-PET is critically useful in RT treatment planning for brain tumors, including gliomas and brain metastases, because it can precisely delineate the target volumes. The abnormal imaging areas for GBM on MET-PET, MRI with Gd, and T2-weighted images do not necessarily coincide. In terms of concordance between MET-PET and MRI, we found the sensitivity 20 mm outside of the Gd-enhanced area (86.4%) and the T2-weighted image area (96.4%) to be most significant. However, 20 mm outside of the T2-weighted image area is too wide an area when attempting to minimize radiation exposure to the normal brain tissue. Accordingly, MET-PET is better suited for precise RT planning for GBM compared to MRI. Next, we compared MRI and MET-PET for RT planning for brain metastases, and quantified the extent of brain metastasis growth. When the tumor volume was ≥ 0.5 mL, a 2-mm margin beyond the gross tumor volume (GTV) on MRI significantly improved the coverage of the GTV on MET-PET. Hence, MET-PET as a biologic imaging tool improves the morphologic visualization of metastasis compared to MRI. To that end, MET-PET and MRI fusion can facilitate RT planning for brain tumors through the accurate identification of the targets.

**Evaluation of the effect of RT**

It was reported that MET-PET could be used to evaluate the outcome of RT for metastatic brain tumors treated with stereotactic radiation therapy with intensity modulated radiation therapy (SRT-IMRT). The T/N ratios determined by MET-PET three and six months after SRT-IMRT were significantly lower than baseline (pre-SRT-IMRT). These significant decreases in MET uptake can be attributed to secondary metabolic changes, deactivation, and obliteration of the target lesion following SRT-IMRT. MET-PET possesses a greater ability to detect early radiation-induced metabolic changes.

---

![Fig. 3 (A) Graph showing the 11C-methionine (MET) tumor-to-normal tissue (T/N) ratio (mean ± standard deviation) of the dynamic study in patients with oligodendroglial tumors. This graph was adapted from data published in reference number 25. Black bar: oligodendroglioma, white bar: anaplastic oligodendroglioma (B) Hematoxylin-eosin stain showing anaplastic oligodendroglioma. (C-E) MET dynamic study showing rapid washout of MET in case B. (C) phase 1, (D) phase 2, (E) phase 3.](image-url)
changes than MRI; use of the latter is limited to determining the change in the size of the target several months post-RT.

**Radiation necrosis (RN) following RT**

RN is one of the most clinically relevant consequences of RT in brain tumors. It is often difficult to distinguish RN from tumor recurrence, since RN mimics the imaging features of malignant glioma on computed tomography or MRI. However, MET has been reported to be very useful in differentiating RN from tumor recurrence. In one study, the T/N ratios of MET in RN, grade III glioma, and grade IV glioma were 1.95 ± 0.60, 3.40 ± 1.04, and 4.29 ± 1.45, respectively. There was a significant difference in MET T/N ratios between RN and grade III glioma (P < 0.005) and between RN and grade IV glioma (P < 0.001). When the cutoff value of the MET T/N ratio was set at 2.51, the sensitivity and specificity for the diagnosis of glioma recurrence were 91.2% and 87.5%, respectively. With respect to other tracers, FDG was reported to be inferior to MET in diagnosing RN. Possible diagnostic tracers for differentiating RN from glioma include 3'-deoxy-3'-18F fluorothymidine (FLT) and 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine (FDOPA). FLT reportedly shows the same level of FDG in both a semi-quantitative and qualitative manner when distinguishing between recurrent tumors and RN for moderate- and high-grade gliomas. In contrast, FDOPA PET was reported to be advantageous over perfusion-MRI in differentiating metastatic brain tumor recurrences from RN by semi-quantitative analysis. In one study, setting the cutoff value of the maximum lesion to maximum background uptake ratio to 1.59 produced a sensitivity and specificity of 90% and 92.3%, respectively.

Bevacizumab (BEV), an endothelial growth factor inhibitor, has been reported to exhibit a strong therapeutic effect against RN. Observing the effects of BEV via MRI was demonstrated by a randomized double-blinded placebo-controlled trial. We evaluated the therapeutic effect of BEV against RN using MET-PET and CHO-PET; the mean values of the MET- and CHO-based T/N ratios of nine patients before BEV administration were 2.19 and 9.24, respectively; these values dropped to 1.71 and 3.19 after BEV therapy, showing reduction rates of 24.4% and 60.7%, respectively. The decrease of CHO-PET uptake was a result of improved vascular permeability due to BEV treatment; however, MET-PET might also reflect suppressed tissue biological activity by BEV as well, because the choline/creatinine ratio as measured by magnetic resonance spectroscopy showed a significant decrease after BEV therapy. These results illustrated the utility of PET in detecting the metabolic changes of RNs in addition to the morphological changes observed by MRI.

**Conclusion**

We reviewed the clinical utility of PET that incorporates three types of tracers (MET, CHO, and FDG) for the scanning of brain tumors. However, PET is unlikely to be used widely because of the short half-life of $^{11}$C, the requirement of a cyclotron to produce positron nuclides, and the high cost of the procedure. PET is not available broadly on demand; therefore, MRI has the advantage in terms of adoption rate and cost. However, we emphasize that PET scans are very informative for tumor diagnosis, including aspects such as tumor viability, grade of malignancy, spread and invasion, and genetic mutations. Since PET can provide metabolic information in addition to the morphologic features that are also obtainable by MRI, it is critically useful in the assessment of treatment outcomes of RT, as well as for differentiating between RN and tumor recurrence. These data lead not only to devising appropriate therapeutic strategies but also to improving the prediction of prognoses of brain tumor patients. Therefore, PET appears to be an essential diagnostic tool that markedly improves brain tumor management.

**Acknowledgment**

We extend our special gratitude to all the staff who devoted their professional attention to this study at the Chubu Medical Center for Prolonged Traumatic Brain Dysfunction.

**Conflicts of Interest Disclosure**

Dr. H. Yano and Dr. J. Shinoda declare that they have no conflicts of interest. Dr. T. Iwama accepted research expenses from Otsuka Pharmaceutical Co. Ltd and Ogaki Tokushukai Hospital in 2013.

All authors have registered online with the Self-reported COI Disclosure Statement Forms through the website for JNS members.

**Ethical Approval**

All studies described in this review were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
References

1) Yonezawa S, Miwa K, Shinoda J, Nomura Y, Asano Y, Nakayama N, Ohe N, Yano H, Iwama T: Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis. J Neurooncol 119: 101–109, 2014

2) Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, Yoshimura S, Maruyama T, Muragaki Y, Iwama T: Metabolic assessment of gliomas using \(^{13}C\)-methionine, \(^{18}F\) fluorodeoxyglucose, and \(^{18}C\)-chlorine positron-emission tomography. AJNR Am J Neuroradiol 29: 1176–1182, 2008

3) Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, Mineura K, Uemura K: Clinical positron emission tomography for brain tumors: comparison of fluorodeoxyglucose F 18 and L-methyl-\(^{13}C\)-methionine. AJNR Am J Neuroradiol 17: 345–353, 1996

4) Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA: Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42: 432–445, 2001

5) Langen KJ, Jarosch M, Mülhensiepen H, Hamacher K, Bröer S, Jansen P, Zilles K, Coenen HH: Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 30: 501–508, 2003

6) De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotch J, Goldman S: Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95: 746–750, 2001

7) Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Erneusus RI, Mendoza G, Weber-Luxenburger G, Lötgen J, Thiel A, Wienhard K, Heiss WD: \(^{18}C\)-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50: 1316–1322, 1998

8) Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K, Senda M, Ishii K, Hirakawa K, Ohno K: Usefulness of L-[methyl-\(^{13}C\)] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103: 498–507, 2005

9) Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, Shimossegawa E, Ito H, Hatazawa J, Okudera T: Cerebral glioma: evaluation with methionine PET. Radiology 186: 45–53, 1993

10) Tovi M, Lilja A, Bergström M, Ericsson A, Bergström K, Hartman M: Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol 31: 417–429, 1990

11) Bustany P, Chatel M, Derlon JM, Darcel F, Sgouropoulos P, Soussaline F, Syrota A: Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-Methionine. J Nucl Med 3: 397–404, 1986

12) Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, Syrota A: \(^{11}C\)-L-methionine uptake in gliomas. Neurosurgery 25: 720–728, 1989

13) Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, Maruyama T, Muragaki Y, Iwama T: Analysis of \(^{11}C\)-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol 29: 1867–1871, 2008

14) Podo F: Tumour phospholipid metabolism. NMR Biomed 12: 413–439, 1999

15) Rohren EM, Turkington TG, Coleman RE: Clinical applications of PET in oncology. Radiology 231: 305–332, 2004

16) Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, Klein JC, Herholz K, Heiss WD: Delineation of brain tumor extent with \(^{11}C\) L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 10: 7163–7170, 2004

17) Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, Jung HW, Lee MC: \(^{11}C\)-methionine PET as a prognostic marker in patients with glioma: comparison with \(^{18}F\)-FDG PET. Eur J Nucl Med Mol Imaging 32: 52–59, 2005

18) Di Chiuro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP: Glucose utilization of cerebral gliomas measured by \(^{18}F\) fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323–1329, 1982

19) Delbeke D, Meyerowitz C, Lapidos RL, Macianas RJ, Jennings MT, Moots PL, Kessler RM: Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195: 47–52, 1995

20) Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, Luxen A, Reznik M: Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39: 778–785, 1998

21) Han ZX, Wang XX, Zhang SN, Wu JX, Qian HY, Wen YY, Tian H, Pei DS, Zheng JN: Downregulation of PAK5 inhibits glioma cell migration and invasion potentially through the PAK5-Egr1-MMP2 signaling pathway. Brain Tumor Pathol 31: 234–241, 2014

22) Bergström M, Collins VP, Ehren E, Ericsson K, Eriksson L, Greitz T, Hallldin C, von Holst H, Långström B, Lilja A: Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using \(^{64}Ga\)EDTA, \(^{11}C\)glucose, and \(^{11}C\)methionine. J Comput Assist Tomogr 7: 1062–1066, 1983

23) Mosskin M, Ericsson K, Hindmarsh T, von Holst H, Collins VP, Bergström M, Ericsson L, Johnström P: Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 30: 225–232, 1989

24) Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T, Sakai N: Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight
from a PET and MR fusion image study. *J Neurol Neurosurg Psychiatry* 75: 1457–1462, 2004

25) Pirotte BJ, Leveiller M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorieve S, David P, Broggi J: Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. *Neurology* 64: 471–481, 2000

26) Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, Heiss WD: Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. *Eur J Nucl Med Mol Imaging* 30: 866–873, 2003

27) Chu S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP: Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. *AJNR Am J Neuroradiol* 26: 266–273, 2005

28) Nojiri T, Nairai T, Aoyagi M, Senda M, Ishii K, Ishiwata K, Ohno K: Contributions of biological tumor parameters to the incorporation rate of [11C]methionine into astrocytomas and oligodendrogliomas. *J Neurooncol* 93: 233–241, 2009

29) Aki T, Nakayama N, Yonezawa S, Takenaka S, Miwa K, Asano Y, Shinoda J, Yano H, Iwama T: Evaluation of brain tumors using dynamic [11C]-methionine-PET. *J Neurooncol* 109: 115–122, 2012

30) Yano H, Ohe N, Nakayama N, Nomura Y, Miwa K, Shinoda J, Iwama T: Dynamic study of methionine positron emission tomography in patients with glioblastoma with oligodendroglial components. *Brain Tumor Pathol* 32: 253–260, 2015

31) Louis DN, Oghahi K, Wiestler OD, Cavenee WK: WHO classification of tumours of the central nervous system, ed 4. Lyon, International Agency for Research on Cancer, 2016

32) Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. *Am J Pathol* 145: 1175–1190, 1994

33) Saito T, Maruyama T, Muragaki Y, Tanaka M, Nitta M, Shinoda J, Aki T, Iseki H, Kurisu K, Okada Y: [11C]-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors. *AJNR Am J Neuroradiol* 34: 85–91, 2013

34) Stockhammer F, Thomale U, Plotkin M, Hartmann C, Von Deimling A: Association between fluoro-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. *J Neurosurg* 106: 633–637, 2007

35) Matsuo M, Miwa K, Tanaka O, Shinoda J, Nishihori H, Tsuge Y, Yano H, Iwama T, Hayashi S, Hoshi H, Yamada J, Kanematsu M, Aoyama H: Impact of [11C] methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. *Int J Radiat Oncol Biol Phys* 82: 83–89, 2012

36) Miwa K, Matsuo M, Shinoda J, Aki T, Yonezawa S, Ito T, Asano Y, Yamada M, Yokoyama K, Yamada J, Yano H, Iwama T: Clinical value of [11C] methionine PET for stereotactic radiation therapy with intensity modulated radiation therapy to metastatic brain tumors. *Int J Radiat Oncol Biol Phys* 84: 1139–1144, 2012

37) Takenaka S, Asano Y, Shinoda J, Nomura Y, Yonezawa S, Miwa K, Yano H, Iwama T: Comparison of [11C] C-methionine, [11C]-choline, and [18F]-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. *Neural Med Chir (Tokyo)* 54: 280–289, 2014

38) Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L: Direct comparison of [18F]-FDG and [11C]-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. *Eur J Nucl Med Mol Imaging* 32: 39–51, 2005

39) Enslow MS, Zollerling LV, Morton KA, Butterfield RI, Kadrmas DJ, Christian PE, Boucher KM, Heilbrun ME, Jensen RL, Hoffman JM: Comparison of [18F]-fluorodeoxyglucose and [18F]-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. *Clin Neurol Med* 37: 854–861, 2012

40) Cicone F, Minniti G, Romano A, Papa A, Scaringi C, Tavanti F, Bozzao A, Maurizi Enrici R, Scopinaro F: Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. *Eur J Nucl Med Mol Imaging* 42: 103–111, 2015

41) Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. *Int J Radiat Oncol Biol Phys* 67: 323–326, 2007

42) Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. *Int J Radiat Oncol Biol Phys* 79: 1487–1495, 2011

43) Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, Gutierrez J, Ryu S, Jain R, Rosenblum M, Mikkelsen T: Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. *J Neurooncol* 94: 63–68, 2009

44) Yano H, Nakayama N, Morimitsu K, Futamura M, Ohe N, Miwa K, Shinoda J, Iwama T: Changes in protein level in the cerebrospinal fluid of a patient with cerebral radiation necrosis treated with bevacizumab. *Clin Med Insights Oncol* 8: 153–157, 2014

*Address reprint requests to: Hirohito Yano, MD, Department of Neurosurgery, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan. e-mail: hirohito@gifu-u.ac.jp*